Also found in: Wikipedia.


a monoclonal antibody that is an interleukin-2 receptor antagonist; used in prophylaxis of acute organ rejection after renal transplantation.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.



Pharmacologic class: Monoclonal antibody

Therapeutic class: Immunosuppressant

Pregnancy risk category B

FDA Box Warning

• Give under supervision of physician experienced in immunosuppressive therapy and management of organ transplant recipients, in facility with adequate diagnostic and treatment resources.


Blocks specific interleukin-2 (IL-2) receptor sites on activated T lymphocytes. Specific binding competitively inhibits IL-2-mediated activation and differentiation of lymphocytes responsible for cell-mediated immunity. Also impairs immunologic response to antigenic challenges.


Powder for injection: 10 mg, 20 mg in single-use vials

Indications and dosages

Prevention of acute organ rejection in kidney transplantation

Adults and children weighing 35 kg (77 lb) or more: 20 mg I.V. 2 hours before transplantation surgery, then 20 mg I.V. 4 days after surgery. Withhold second dose if complications, hyper-sensitivity reaction, or graft loss occurs.

Children weighing less than 35 kg (77 lb): 10 mg I.V. 2 hours before transplantation surgery, then 10 mg I.V. 4 days after surgery. Withhold second dose if complications, hypersensitivity reaction, or graft loss occurs.


• Hypersensitivity to drug

• Pregnancy or breastfeeding


Use cautiously in:

• elderly patients

• females of childbearing age.


Give by central or peripheral I.V. route only.

• Reconstitute by adding 5 ml of sterile water for injection to vial for bolus injection, or dilute with normal saline solution or dextrose 5% in water to a volume of 50 ml and infuse over 20 to 30 minutes. Discard any remaining product after preparing each dose.

• Don't infuse other drugs simultaneously through same I.V. line.

• Know that drug should be used only as part of regimen that includes cyclosporine and corticosteroids.

Adverse reactions

CNS: headache, insomnia, paresthesia, dizziness, drowsiness, tremor, anxiety, confusion, coma, seizures

CV: palpitations, edema, chest pain, ECG abnormalities, hypotension, hypertension, prolonged QT interval

EENT: blurred vision, eye irritation, tinnitus, earache, epistaxis, nasopharyngitis, sinusitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia, oral blisters, oral candidiasis, GI hemorrhage

GU: urinary incontinence, intermenstrual bleeding, oliguria, renal failure

Hematologic: anemia, disseminated intravascular coagulation, hemorrhage, neutropenia, thrombocytopenia Metabolic: hypokalemia, hypomagnesemia, hyperglycemia, acidosis, hypoglycemia, hyperkalemia

Musculoskeletal: bone, back, neck, or limb pain

Respiratory: dyspnea, cough, hypoxia, tachypnea, hemoptysis, upper respiratory tract infection, pleural effusions

Skin: bruising, pruritus, dermatitis, skin lesions, diaphoresis, night sweats, erythema, hyperpigmentation, urticaria

Other: fever, lymphadenopathy, facial edema, bacterial infection, herpes simplex infection, injection site erythema, hypersensitivity reaction, sepsis


Drug-drug. Immunosuppressants: additive immunosuppression

Drug-diagnostic tests. Calcium, glucose, potassium: increased or decreased levels

Hemoglobin, neutrophils, platelets: decreased values

Triglycerides: increased levels

White blood cells: decreased levels

Drug-herbs. Astragalus, echinacea, melatonin: interference with immunosuppressant action

Patient monitoring

Watch for signs and symptoms of hypersensitivity reaction. Keep emergency drugs at hand in case these occur.

• Monitor vital signs and observe patient frequently during I.V. infusion.

• Monitor laboratory values and drug blood level.

Patient teaching

• Teach patient about purpose of therapy. Explain that drug decreases the risk of acute organ rejection.

• Tell patient he may be more susceptible to infection because of drug's immunosuppressant effect.

• Inform patient that he'll need lifelong immunosuppressant drug therapy.

• Advise women of childbearing age to use reliable contraception before, during, and for 2 months after therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A high-affinity, mouse–human chimeric monoclonal antibody raised against the alpha chain (CD25) of the IL-2 receptor on T cells. It is used to prevent or minimise the rejection of transplanted solid organs, and meant to complement other drugs.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.


Simulect® Nephrology A high-affinity, monoclonal antibody used to minimize acute rejection post renal transplant, which complements antirejection drugs–eg, Neoral®. See Kidney transplant.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.


A chimeric monoclonal antibody to the alpha chain (CD 25), one of the three transmembrane protein chain receptors of INTERLEUKIN 2R. This interleukin plays an important role in T lymphocyte proliferation. On resting T cells the level of expression of CD 25 is low but allogenic stimulation after organ grafting causes it to rise. This provides specificity for a means of control of graft rejection. Trials have suggested that basiliximab can reduce graft rejection by one third. A brand name is Simulect.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
The patient received induction therapy with basiliximab followed by an immunosuppressive regimen consisting of tacrolimus, mycophenolate mofetil (MMF), and prednisolone.
The patient received combination immunosuppressive therapy with methylprednisolone, tacrolimus, mycophenolate mofetil, and basiliximab.
The cold ischemia time was 7 hours and the patient was induced with basiliximab and methylprednisolone.
M2 PRESSWIRE-August 22, 2019-: Investigation Report on China's Basiliximab Market, 2019-2023: Incidence, Transplantation, Market Status, Retail Prices, Major Factors & Prospects
Induction treatment was used and consisted of antithymocyte globulin (ATG 5-8mg/kg total) for the majority of the patients and Basiliximab (20 mg IV day 0 and 4) was given to low immunological risk kidney transplant recipients.
During his liver transplantation, he received basiliximab and hydrocortisone for intraoperative immunosuppression.
The immunosuppressive protocol consists of induction with intravenous methylprednisolone administered intraoperatively and a second dose after 24 hours, and two doses of basiliximab at day zero and day four.
day 11 and 4 mg/day after 3 months); a minority of patients (less than 10%), enrolled in clinical studies, might have been induced with Basiliximab and/or treated with Tacrolimus, Everolimus, or Sirolimus as alternatives; Azathioprine was also substituted for Mycophenolate in gastrointestinal intolerant patients.
Patients in the ATG study group were compared with a historical cohort of patients with pretransplant renal dysfunction (eGFR < 60 mL/min/1.73[m.sup.2] under the MDRD4 formula on the day of LT), who underwent LT and received monoclonal interleukin-2-receptor (basiliximab) as induction therapy (BAS group).
Her immunosuppressive regimen included Basiliximab induction, tacrolimus, mycophenolate mofetil, and steroids.
Regarding immunosuppression, she was given standard regimen of our institution for high risk patient including perioperative plasmapheresis and induction therapy with basiliximab, then maintenance regimen with a combination of cyclosporine, mycophenolate, and prednisone.